Weight-Based Torsemide Dosing in Subjects With Heart Failure

PHASE4CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

April 17, 2018

Primary Completion Date

March 14, 2022

Study Completion Date

March 14, 2022

Conditions
Heart Failure
Interventions
DRUG

Torsemide

These subjects who are randomized to a weight-based torsemide regimen will be instructed via phone encounters three times per week to take an individualized dose of torsemide based on their current weight and symptoms. These subjects will have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.

OTHER

Standard Outpatient Heart Failure Management

Those subjects randomized to standard outpatient management group will be prescribed a daily fixed dose of a loop diuretic upon discharge from the hospital. These subjects will have a follow-up appointment within one week of discharge where all medications including loop diuretic type, dose and frequency will be managed at the discretion of the subject's physician. These subjects will also have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.

Trial Locations (1)

10461

Jacobi Medical Cent, The Bronx

All Listed Sponsors
lead

New York City Health and Hospitals Corporation

OTHER

NCT03187509 - Weight-Based Torsemide Dosing in Subjects With Heart Failure | Biotech Hunter | Biotech Hunter